BBPVirtus LifeSci Biotech Products ETF
Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Products Index.
By Virtus · Launched 2014
Annual Cost
0.34%
#1,567 of 6,040 · low cost
Fund Size
$117M
#2,940 of 6,040 · mid-size
Return (1Y)
+52.1%
Track Record
11 years
#1,250 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$12,553+25.5%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
LifeSci Biotechnology Products Index
Holdings
By weightConcentration
Top 10 holdings = 26.7% of funddiversified
IMMUNITYBIO INC
4.8%
DREYFUS GOVERNMENT CASH MANAGEDGCXX
3.2%
APELLIS PHARMACEUTICALS INC
2.6%
KALVISTA PHARMACEUTICALS INC
2.5%
MODERNA INC
2.5%
IOVANCE BIOTHERAPEUTICS INC
2.4%
MIRUM PHARMACEUTICALS INC
2.4%
AXSOME THERAPEUTICS INC
2.2%
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
2.1%
ROIVANT SCIENCES LTD
2.1%
Asset allocation
Stocks
99.8%
Cash
0.2%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
25.2%High
Year-on-year price swings
Max drawdown
-44.2%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.88Decent risk-adjusted returns
Sortino (3Y)
1.31Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Products Index.
- Strategy
- Invests primarily in common stock of U.S. biotechnology companies with FDA-approved drug therapies, using a passive indexing approach to replicate the LifeSci Biotechnology Products Index. Concentrates investments in the biotechnology sector, targeting companies with market capitalizations of at least $500 million.
- Inception date
- December 16, 2014
- Fund family
- Virtus
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BBP to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18